Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.
AERD
Eosinophilic sinusitis
Leukotriene
Omalizumab
Severe asthma
Journal
Allergology international : official journal of the Japanese Society of Allergology
ISSN: 1440-1592
Titre abrégé: Allergol Int
Pays: England
ID NLM: 9616296
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
26
04
2019
accepted:
06
05
2019
pubmed:
27
6
2019
medline:
21
12
2019
entrez:
26
6
2019
Statut:
ppublish
Résumé
The characteristics in AERD are severe adult-onset asthma, eosinophilic rhinosinusitis with nasal polyposis, and CysLT overproduction. The cause of AERD have remained unclear, however the decrease in the production of PGE2 caused by the reduction in COX-2 activity is considered to main pathological mechanism of AERD. The mast cell activation and the interaction between platelets and granulocytes are lead to the CysLT overproduction and severe eosinophilic inflammation. The ongoing activation of mast cells is important key pathogenesis in not only stable AERD but exacerbated AERD by aspirin and NSAIDs. In recent years, type 2 inflammation caused by ILC2 activation in patients with AERD have been attracting attention. Omalizumab is effective option for AERD via suppression of mast cell activation and CysLT overproduction. Dupilumab improves sinus symptoms especially in patients with AERD. In near future, anti-platelet drug, CRTH2 antagonist, and anti-TSLP antibody may be useful candidates of therapeutic options in patients with AERD.
Identifiants
pubmed: 31235242
pii: S1323-8930(19)30058-9
doi: 10.1016/j.alit.2019.05.001
pii:
doi:
Substances chimiques
Anti-Asthmatic Agents
0
Anti-Inflammatory Agents, Non-Steroidal
0
Aspirin
R16CO5Y76E
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-295Informations de copyright
Copyright © 2019 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.